Introduction
One of the hallmarks of cancer is reprogramming energy metabolism (1) . Cancer cells use both glucose and glutamine as a substrate to generate energy and to provide building blocks, such as amino acids, nucleosides, and fatty acids (2) (3) (4) . Currently, increased glucose uptake and enhanced glycolytic metabolism of tumors is used for tumor positron emission tomography (PET) imaging with 2-[ 18 F]fluoro-2-deoxyglucose ([ 18 F]FDG). However, FDG has limitations in several tumor entities and settings. Therefore, imaging of other fundamental processes in tumors would be of great interest for early cancer detection, therapy monitoring, or prediction of resistance to chemotherapy (5) .
The high rate of glucose and glutamine flux to increase cell mass results in an increase of oxidative intermediates, an altered redox potential, and excessive reactive oxygen species (3). Glutathione is the major thiol-containing endogenous antioxidant and serves as a redox buffer against various sources of oxidative stress (4, 6) . The system x C À is a heterodimeric transporter, composed of a light chain, xCT (SLC7A11), and heavy chain, 4F2hc (SLC3A2), which mediates the sodium-independent cellular uptake of cystine in exchange for intracellular glutamate at the plasma membrane (7). Intracellularly, cystine can then be converted to 2 molecules of cysteine, which is used for glutathione synthesis. Another main function of system x C À is maintenance of a cysteine-cystine redox cycle in the extracellular compartments (8) . In patients with cancer, it has become evident that the x C À transporter plays an important role in growth (9) and progression of cancer and glutathionebased drug resistance (10) . CD44 is an adhesion molecule important for tumor cell invasion and metastasis and is a marker for cancer stem cells (11, 12) . Quite recently, a CD44 splice variant has been reported to regulate redox status in cancer cells by stabilizing the xCT subunit of system x C À
(13). (4S)-4-(3-[
18 F]fluoropropyl)-L-glutamate (BAY 94-9392, and herein referred to [ 18 F]FSPG) is a novel 18 Flabeled glutamate derivative for PET imaging. Specific transport of [ 18 F]FSPG via the x C À transporter was shown in cell competition assays and xCT knockdown cells, and an excellent tumor visualization was achieved in animal tumor models (14) . Tumor-specific adaptations of the intermediary metabolism and the function of system x C À and CD44 in glutathione biosynthesis and the cysteine-cystine redox cycle are schematically illustrated in Supplementary Fig. S1 . 
Materials and Methods

Study design
This is an open-label, nonrandomized, single-dose explorative study conducted to evaluate the safety, tolera- 18 F]FSPG as extrapolated from biodistribution studies in mice to humans were 5.1 mSv for a male and 6.5 mSv for a female subject (unpublished data). Our study protocol was approved by both the Institutional Review Board of the Asan Medical Center (University of Ulsan College of Medicine, Seoul, Republic of Korea) and the Korea Food and Drug Administration. This study was conducted in accordance with the Helsinki Declaration. All patients provided written informed consent before participation in the study.
Radiopharmaceutical preparation
Synthesis of the precursor and subsequent 18 F labeling using 18 F-fluoride were conducted as described recently (14) . Each batch of [ 18 F]FSPG that was produced met the criteria listed in the specification for appearance, identity, radiochemical and chemical purity, radioactivity concentration, specific activity, pH, bacterial endotoxin level, and sterility before being released. The final product was formulated as a sterile solution for intravenous injection. The amount of drug substance per injected unit was 300 AE 30 MBq and 100 mg or less mass dose. The specific activity was 18.2 GBq/mmol or more. The decay-corrected radiochemical yield was 29.1% AE 5.0% (range, 20.5%-40.5%), and the radiochemical purity was 90.8% AE 0.5% (range, 90.2%-91.6%).
Patients
The 18 F]FSPG PET/CT acquisition was conducted during 3 time intervals. The first interval ranged from 0 (immediately after tracer injection) to 45 minutes, the second interval from 60 to 75 minutes, and the third interval from 105 to 120 minutes. For attenuation correction of the PET scan, a low-dose CT (80 kV CARE Dose 4D, 31 mAs) without contrast medium administration was acquired for each imaging window. The total radiation exposure from the 3 CT examination did not exceed 3 mSv. Five, consecutive skull base-to-mid thigh or whole-body tumor imaging (top of the skull to the mid-thigh or feet) were acquired for the first imaging interval of 0 to 45 minutes along with the injection of 300 AE 10 MBq of [ 18 F]FSPG. Each PET scan was acquired for 0.5, 0.5, 1, 2, and 2 minutes per bed position, respectively. During the second and the third imaging intervals, 1 skull base-to-mid thigh or whole-body tumor image per each imaging window was acquired for 2 minutes per bed using the same acquisition parameter applied for the previous scan during the first imaging interval. Patients were asked to void their urinary bladder immediately after the first scan. Urinary bladder voiding was also encouraged before and after the second and third imaging session. Scans were corrected for random and scattered using the models implemented by the software supplied by the scanner manufacturer; they were also corrected for attenuation as estimated by the CT image. Data were reconstructed using the manufacturer-provided ordered-subset expectation maximization algorithm. No correction for partial volume effects was conducted.
Image analysis
The PET/CT studies were assessed visually and quantitatively by the consensus of 2 experienced nuclear medicine physicians who were informed of all available [ 18 F]FDG PET imaging, clinical, and laboratory findings. The readers reviewed all images to determine whether the image quality was adequate for interpretation. The number, location, size, extent, and intensity of all abnormal uptakes in relation to the background uptake in normal comparable tissues were described. Intensity features were classified as major, minor accumulation, or absent. Lesions with minor or major accumulation were regarded as positive. For dynamic assessment of [ 18 F]FSPG uptake in tumor and normal organs, spherical volumes of interest with a diameter of 1.5 or 1.2 cm were placed on normal organs and tumor, respectively. The selected tumor lesion was histologically proven to be cancer. A volume of interests on liver and descending thoracic aorta as the blood pool was drawn as previously recommended (16) . For quantitative analysis, the volume of interest was drawn semiautomatically using the vendor's software (TrueD, Siemens and CD44 were semiqualitatively assessed using a scale of 0, 1þ (weak), 2þ (medium), and 3þ (strong) with a sample being reported as positive if greater than 10% of the cells in the sample were positively stained. The correlation between the intensity of immunohistochemical staining and SUV max of the corresponding lesion on the PET/CT was then assessed.
Statistical analysis
Data were reported as mean AE SD unless otherwise specified. A P value of <0.05 was considered to be statistically significant. Comparison of quantitative parameters was conducted using the paired t test. The correlation of [ 18 F]FSPG uptake (SUV max ) with the intensity of x C À transporter and CD44 IHC was assessed using Spearman rank correlation coefficients (r). The significance level was calculated assuming that 
Biodistribution of [
18 F]FSPG The overall image quality was adequate for diagnosis in all patients, and all patients showed initially high uptake in the kidneys and pancreas. The kidneys showed a rapid, intense uptake, which gradually decreased (11.1 AE 1.5 SUV mean at 60 minutes postinjection), whereas the pancreas and scalp activity continuously increased, reaching a plateau at approximately 15 to 60 minutes postinjection (SUV mean value determined at 60 minutes for the pancreas was 8.6 AE 4.5 and the scalp 2.0 AE 0.5, respectively). This uptake and excretion pattern resulted in prominent signals from the kidney, pancreas, and bladder, as seen on delayed images (Fig. 1) . Liver, breast, and bone marrow showed prolonged uptake, which resulted in normal visualization on delayed images. [ 18 F]FSPG cleared rapidly from the blood pool with 0.8 AE 0.2 SUV mean of blood pool activity 60 minutes following injection. However, vascular activity was visible on the most of the PET acquisitions but was then barely distinguishable from the low-level background activity 105 minutes following injection (SUV mean , 0.4 AE 0.1). No focal or elevated uptake was observed in the brain, muscle, small or large intestinal track, or on the cortical or trabecular bone surfaces. In some patients, delayed activity accumulation in the stomach was observed. Table S2 and Supplementary Fig. S2 . Research. Supplementary Fig. S3 ). The SUVR of NSCLC were comparable (P ¼ 0.12), although in breast cancer, the SUVR of [
18 F]FDG differed significantly from that of [ 18 F]FSPG (P < 0.05, Table 2 ). For more information on a patient with low [
18 F]FSPG uptake, see the Supplementary Fig. S4 and Supplementary Movie S2. (Fig. 4B) . Statistical analyses revealed a significant correlation of [ 18 F]FSPG SUV max 60 minutes after injection with both x C À transporter (r ¼ 0.68, P < 0.01) and CD44 expression (r ¼ 0.77, P < 0.01, Fig. 4) . SUVR also correlated with immunohistochemical staining results in the same manner (data not shown). A significant correlation was also observed between immunohistochemical staining of xCT and CD44 as shown in Supplementary  Fig. S5 (r ¼ 0.65, P < 0.05). Two patients with NSCLC and 1 patient with breast cancer (liver metastasis) with both strong positive xCT and CD44 expression showed a very high [ 18 The biodistribution data showed increasing uptake up to 60 minutes after injection in pancreas and scalp, whereas predominant renal excretion resulted in high initial uptake in the kidneys, which decreased slowly over time. In human transporter is predominantly expressed in the brain, pancreas (18) , stromal, and immune cells. In monkeys, xCT protein distribution was shown in the kidney and duodenum (19) . A recent study suggests that the Slc7a11 gene is a major genetic regulator of pheomelanin in hair and melanocytes (20) . The critical role of x C À transporter in the control of pigmentation may correspond with the scalp uptake of [ 18 F]FSPG in this study. Our biodistribution data are therefore in accordance with previous studies with xCT and [
18 F]FSPG biodistribution in animals (14) . No uptake in healthy brain tissue is likely due to inability of the tracer to cross the intact blood brain barrier. High normal uptake in the pancreas and kidneys and excretion in bladder likely precludes the use of [ 18 F]FSPG in assessing tumors in these organs, as shown in Fig. 2 (21) . NCI60 panel studies revealed that the expression level of cystathionine b-synthase, the key enzyme of the transsulfuration pathway, is the highest in breast cancer cell lines but lower in lung cancer cell lines (22) . Another pathway for cysteine availability is the g-glutamyl cycle, which allows the efficient use of glutathione for cysteine storage (23) . Altered expression of g-glutamyl transpeptidase has been found in human tumors of the liver, lung, and breast (24, 25) . Fibroblasts, activated macrophages, or dendritic cells may also supply cancer cells with cysteine as shown in lymphoid cells, which are unable to express the system x C À (26, 27) . These cells may take up cystine from the extracellular space by using the system x C À transporter, convert cystine to cysteine intracellularly, and release cysteine into the extracellular space, where it is available to cancer cells via transporters, such as those from the alanine-serine-cysteine family. All these mechanisms may partially explain the observed differences in [ 18 F]FSPG uptake between NSCLC and patients with breast cancer. The relative contribution of different mechanisms for cysteine availability needs to be further explored.
Our data showed that even a 2þ immunostaining score for xCT does not necessarily result in a high [ 18 F]FSPG uptake. Meanwhile, all patients with negative xCT or CD44 had a low level of [ 18 F]FSPG uptake. Interestingly, 3 patients with both strong positive xCT and CD44 expression showed a very high [ 18 F]FSPG SUV max . All these findings suggest a relationship of [ 18 F]FSPG uptake with the staining intensity of IHC if both the xCT subunits of system x C À and CD44 are considered. A recent study reported a role of a CD44 splice variant in regulating the redox status in cancer cells by stabilizing the xCT subunit at the cell membrane (13) . Although the CD44 antibody used in this study is not able to distinguish between normal and the CD44 splice variant, the CD44 splice variant can be assumed to be the dominant CD44 form in tumors (28) . Our results may confirm an important role of CD44 for the proper functioning of the system x C À .
However, IHC data show only protein expression and does not provide any information on the functional activity, which is of great importance when studying transporter molecules. Staining of the xCT subunit was observed in the membrane and/or cytosol. No relationship was found between [ 18 F]FSPG uptake and localization of xCT staining. In addition, we may not explain a low level of [ 18 F]FSPG uptake even though with positive xCT 2þ and CD44 2þ immunostaining in patient 5. We need more studies to clarify these issues. IHC using a specific antibody to the CD44 splice variant may help to better understand this situation. 
